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Distribution of neocarzinostatin conjugated to biotinylated chimeric
monoclonal antibody Fab fragments after adminstration of avidin
E Otsuji, T Yamaguchi, H Matsumura, K Yamamoto, H Tsuruta, Y Yata, H Nishi, K Okamoto,
K Kitamura and T Takahashi
First Department of Surgery, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602, Japan.
Summary We have developed chimeric Fab fragments of MAb A7 (chA7Fab) and have reported on their
potential usefulness as a carrier of neocarzinostatin (NCS). However, a large amount of chA7Fab accumulates
in the kidneys which might cause renal failure. This was one of the major side-effects of the chA7Fab-NCS
immunoconjugate administered to humans. To decrease the kidney accumulation of chA7Fab, chA7Fab was
biotinylated and administered with a subsequent injection of avidin to nude mice with pancreatic cancer. The
accumulation of biotinylated chA7Fab in the blood and the kidneys decreased significantly after the injection
of avidin. In a separate experiment with biotinylated chA7Fab-NCS, the blood and kidney accumulation
decreased significantly after the injection of avidin. These findings suggest that the injection of biotinylated
chA7Fab complexed with NCS followed by avidin may be safer and may permit the administration of larger
doses of NCS without the subsequent development of renal failure.
Keywords: biotinylated antibody; chimeric antibody; avidin; targeting chemotherapy; monoclonal antibody A7;
pancreatic cancer
Introduction
Pancreatic cancer is one of the most lethal of all cancers. One
of the reasons for its high mortality is the lack of effective
chemotherapy. A number of murine monoclonal antibodies
(MAbs) have been linked to various anti-tumour drugs,
cytotoxins and enzymes in an attempt to increase the
effectiveness of chemotherapy (Apelgren et al., 1990). We
have also produced MAb A7, which reacts with pancreatic
and colonic carcinomas, from human colonic carcinomas,
and covalently conjugated it with the anti-cancer drug,
neocarzinostatin (NCS) (Fukuda, 1985). A7-NCS has been
used clinically for the treatment of patients with advanced
colorectal and pancreatic cancers. However, human anti-
mouse antibody (HAMA) was detected in all patients who
received A7-NCS (Takahashi et al., 1993). HAMA usually
increases the clearance of the administered MAb, thus
reducing the MAb tumour accumulation and possibly
resulting in lower therapeutic efficacy of the MAb-drug
conjugate.
In Fujita's previous study, more than 70% of the NCS
was inactivated by the serum within 120 min (Fujita et al.,
1970). In general, because the Fab fragments of MAbs are
able to penetrate target tumours, they may be more suitable
as carriers of anti-cancer agents such as NCS which are
inactivated rapidly in the blood.
For these reasons, we have developed chimeric Fab
fragments of MAb A7 (chA7Fab) (Yamaguchi et al., 1993)
as a carrier of NCS. In a previous study using nude mice
bearing pancreatic carcinoma (which reacts with MAb A7), a
larger amount of 1251-labelled chA7Fab accumulated in the
pancreatic carcinoma compared with that of '25I-labelled
MAb A7. Regarding normal tissue accumulation, however,
more chA7Fab than 125I-labelled MAb A7 accumulated in the
kidney because most of the intravenously injected chA7Fab
was cleared via the kidney. Because renal dysfunction is one
of the major side-effects of NCS chemotherapy in human, the
kidney accumulation of chA7Fab should be minimised when
it is administered as a carrier of NCS.
The association constant of the avidin-biotin binding is
approximately 1015 M-1, and much greater than that of
antigen-antibody interactions (Green, 1963). Because avidin
has four biotin-binding sites per molecule, aggregates formed
by avidin and biotinylated antibody are produced if avidin is
injected following the administration of biotinylated anti-
body. Once such aggregates are formed in the body, they
could be taken up rapidly by the reticuloendothelial system
and their accumulation in the blood and kidney should
decrease accordingly. In this study we investigated the in vivo
distribution of biotinylated chA7Fab and biotinylated
chA7Fab-NCS after the administration of avidin which
appeared to decrease the accumulation of chA7Fab in the
kidney.
Materials and methods
Cell line and tumour xenografts
The human pancreatic carcinoma cell line, HPC-YS, used in
this study was established from a ductal cell adenocarcinoma
of the human pancreas and was obtained from N Yamaguchi
(Research Institute of Neurology and Geriatrics, Kyoto
Prefectural University of Medicine, Japan) (Otsuji et al.,
1993). HPC-YS cells were maintained in RPMI-1640 medium
supplemented with 10% fetal bovine serum (FBS) (Flow
Laboratories Inc., Rockville, MD, USA). Cultured HPC-YS
cells were harvested by brief treatment with EDTA, washed
in phosphate-buffered saline (PBS) and resuspended in PBS.
Approximately 5 x 106 viable cells were injected subcuta-
neously (s.c.) into the left flank of athymic 8-week-old male
mice (BALB/C, nu-nu) (SLC Co., Shizuoka, Japan). A
tumour mass detected in all the mice injected with the
HPC-YS cells. These mice were treated humanely according
to the guidelines in our Institute.
Preparation and purification of chA7Fab
Murine MAb A7 is an IgG, and has been reported to react
with 77% of human pancreatic carcinomas tested, as well as
with 70% of the human colonic carcinomas tested (Otsuji et
al., 1993). MAb A7 does not react immunohistochemically
with normal pancreatic tissues (Otsuji et al., 1990). ChA7Fab
was produced as described previously (Yamaguchi et al.,
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Figure 1 The accumulation of 125I-labelled biotinylated chA7Fab in the blood, HPC-YS tumours and the normal tissues of mice
with or without the subsequent administration of avidin (a, blood; b, tumour; c, heart; d, liver; e, spleen; f, pancreas; g, colon; h,
kidney). The mice received an injection of avidin in 100p1 of 50mM HEPES in 5% mannitol buffer or the same solution without
avidin, respectively, at 1, 6, 12 and 24h after the injection of 125I-labelled biotinylated chA7Fab. The pattern of tumour
accumulation of 125I-labelled biotinylated chA7Fab with the subsequent administration of avidin was similar to that without
administration of avidin. The blood concentration of '25I-labelled biotinylated chA7Fab was significantly lower following the
administration of avidin than without its administration at 1 and 6h after the injection of 125I-labelled biotinylated chA7Fab. The
kidney accumulation of 1251-labelled biotinylated chA7Fab was significantly lower with the subsequent administration of avidin than
it was without the administration of avidin at I and 6h after antibody injection. The accumulation of 125I-labelled biotinylated
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1993). Briefly, a murine light-chain variable region gene was
joined to a human K light-chain constant region gene. A
murine heavy-chain variable region gene was joined to a
human y, heavy-chain constant region gene to construct a
human-mouse chimeric heavy-chain gene. The plasmid
DNAs were introduced into AH22 yeast cells as described
previously. After incubation in YPD medium for 3 days, the
cellular debris was removed from the medium by centrifuga-
tion and purified using a CM Sepharose 4B anti-human IgG
column.
Neocarzinostatin conjugation to chA7Fab
ChA7Fab was conjugated to NCS (Kayaku, Tokyo, Japan)
with N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP) as
described previously by Yamaguchi et al. (1993). The
conjugation ratio was 1 mol of NCS per mol of chA7Fab.
Preparation of radiolabelled chA7Fab and chA7Fab-NCS
Radiolabelling of chA7Fab with 1251 (Amersham Japan Ltd.,
IMS 30, Japan) was performed by the chloramine-T method
(Hunter and Greenwood, 1962). lodinised chA7Fab was
separated from unconjugated reagents by gel filtration on a
Sephadex G-25 column. ChA7Fab-NCS was radiolabelled
with 1251 by the same method. ChA7Fab and chA7Fab-NCS
was labelled with 1251 to a specific activity of 4.5 XCi g
and 4.2 MCi ug-1 respectively.
Biotinylation of 125I-labelled chA7Fab and '25I-labelled
chA7Fab-NCS
NHS-biotin (180 Mug) (Pierce 23225, IL, USA) in dimethyl
sulphoxide (DMSO) was added to 120 jug of 1251-labelled
chA7Fab in 50 mM sodium bicarbonate buffer, pH 8.5.
Following incubation on ice for 90 min, the preparations
were incubated for 30 min at room temperature. 1251-labelled
biotinylated chA7Fab was separated from unreacted biotin
by gel filtration on a Sephadex G-25 column. 1251I-labelled
biotinylated chA7Fab-NCS was also biotinylated by the
same method. '251-labelled biotinylated chA7Fab and 1251_
labelled biotinylated chA7Fab-NCS was stored at 4°C in
0.1 M sodium phosphate, pH 7.0 until use.
Biodistribution of '25I-labelled chA7Fab and '25I-labelled
chA7Fab-NCS after administration ofavidin in nude mice
bearing tumours
The distribution of '251-labelled biotinylated chA7Fab after
the administration of avidin was investigated in athymic nude
mice bearing HPC-YS tumours. Fourteen days after
inoculation, the tumour-grafted mice were divided into two
groups. Thirty-two mice were divided into two groups and
mice in both groups injected intravenously with 0.7,Ci of
'25I-labelled biotinylated chA7Fab in 100 i1 of PBS. Four
mice from each group were injected intravenously with 30 ,ug
of streptavidin (Sigma, MO, USA) in 100 ,il of 50 Mm
HEPES in 5% mannitol buffer, pH 7.4 or the same solution
without streptavidin respectively at 1, 6, 12 and 24 h after the
injection of '251-labelled biotinylated chA7Fab. They were
killed 30 min later and dissected. After dissection, the
tumours, blood and normal organs (heart, liver, spleen,
pancreas, colon and kidney) were weighed. The mean weight
of the tumours was 145 mg. The radioactivity in each tissue
was then measured using a y-scintillation counter (Auto-
Gamma, 5000, Packard). The results from the various tissues
were expressed as c.p.m. g-' and compared with each other.
To compare the kinetics of '25I-labelled biotinylated chA7Fab
in each group, the results were presented as %ID g-' (%
injected dose of radioactivity per g). The distribution of 251-
labelled biotinylated chA7Fab-NCS after the administration
of avidin was also examined in athymic nude mice bearing
HPC-YS tumours. '25"-labelled biotinylated chA7Fab-NCS
was injected with or without the subsequent administration of
streptavidin and tumours, blood and normal organs (heart,
liver, spleen, pancreas, colon and kidney) were collected. The
weight and radioactivity of each tissue was measured and
then the results were presented as %ID g-'. Student's t-test
was used to check for statistically significant differences.
Results
Biodistribution of'25"-labelled chA7Fab after administration of
avidin in nude mice bearing tumours
The pattern of tumour accumulation of '25I-labelled
biotinylated chA7Fab with the subsequent administration of
avidin was similar to that when avidin was not administered.
The tumour accumulation of "2s1-labelled biotinylated
chA7Fab with and without the administration of avidin
decreased linearly with time. In contrast, the concentration of
1251-labelled biotinylated chA7Fab in the blood was lower
with the administration of avidin than without it. Significant
differences were observed between the two groups at 1 and
6 h after injection (P<0.05). As for normal tissues, the
kidney accumulation of 125I-labelled biotinylated chA7Fab
was lower with the administration ofavidin than that without
it. Significant differences were observed between the two
groups at 1 and 6 h after injection (P<0.05). The
accumulation of "251-labelled biotinylated chA7Fab in the
spleen and the liver was higher with the administration of
avidin than that without it. Significant differences were
observed between the two groups at 1 and 6 h after injection
for the spleen and the liver (P<0.05) (Figure 1).
Biodistribution of '25"-labelled chA7Fab-NCS after
administration of avidin in nude mice bearing tumours
The tumour accumulation of '25I-labelled biotinylated
chA7Fab-NCS with the administration of avidin was
almost identical with that without administration of avidin.
In contrast, the concentration of "25I-labelled biotinylated
ch7Fab-NCS in the blood was lower with the administration
of avidin than without it. Significant differences were
observed between the two groups at 1, 6 and 12 h after
injection (P<0.05). The kidney accumulation of '251-labelled
biotinylated chA7Fab-NCS was lower with the administra-
tion of avidin than that without it. Significant differences
were observed between the two groups at 1 and 6 h after
injection (P<0.05). The accumulation of '251-labelled
biotinylated chA7Fab-NCS in the spleen and the liver was
higher with the administration of avidin than that without it.
Significant differences were observed between the two groups
at 1 and 6 h after injection for the spleen and at 1 h for the
liver (P<0.05) (Figure 2).
Discussion
We have reported that MAb A7 can be linked covalently to
NCS and that this conjugate can be used to treat patients
with colorectal cancer. Although some of the patients who
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chA7Fab in the spleen and the liver was higher following the administration of avidin than it was without the administration of
avidin. Significant differences were observed between the two groups at 1 and 6h after the antibody injection for the spleen and the
liver. A, with the subsequent administration of avidin; B, no avidin administration; point, mean; bar, s.d.; *, significant difference
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Figure 2 The accumulation of 125I-labelled biotinylated chA7Fab-NCS in the blood, HPC-YS tumours and the normal tissues of
mice with or without the subsequent administration of avidin (a, blood; b, tumour; c, heart; d, liver; e, spleen; f, pancreas; g, colon;
h, kidney). The mice received an injection of avidin in 100 p1 of 50 mm HEPES in 5% mannitol buffer or the same solution without
avidin, respectively, at 1, 6, 12 and 24h after the injection of 1251-labelled biotinylated chA7Fab-NCS. The pattern of the
accumulation of 5I-labelled biotinylated chA7Fab-NCS in each tissue with or without the subsequent administration of avidin
was similar to that of 1251-labelled biotinylated chA7Fab. A, with the subsequent administration of avidin; B, no avidin
administration; point, mean; bar, s.d.; *, significant difference (P<0.05).
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have been treated with A7-NCS have had a partial
regression of their tumours, HAMA was produced in all
patients who received A7-NCS (Takahashi et al., 1993).
HAMA production should decrease when NCS conjugated to
a human/mouse chimeric MAb is administered to humans,
because the origin of the Fc portion of the chimeric MAb,
which is the most immunopotent region of intact MAbs
(Spiegelberg et al., 1965), is human. Fujita et al. (1970)
reported that more than 70% of the anti-tumour activity of
NCS was inactivated by 10% mouse serum within 120 min in
an in vitro experiment. In general, the small variable fragment
of the MAb molecule has the ability to leave the vascular
space rapidly and to penetrate easily into target tumour
tissue. Thus, Fab fragments of MAb A7 may be suitable as
carriers of anti-cancer agents like NCS which are inactivated
rapidly in the blood. For these reasons, we have prepared
chA7Fab and have conjugated it to NCS. ChA7Fab
specifically accumulated in the tumour (Otsuji et al., 1995)
and the conjugate showed greater anti-tumour activity
against human pancreatic cancer growth in nude mice than
did A7-NCS and completely suppressed tumour growth
(Otsuji et al., 1996). However, a large amount of chA7Fab
accumulated in the kidney, consistent with the results of
Hansson et al. (1988) who have demonstrated the rapid
clearance of non-Fc-bearing antibody fragments. This
clearance is thought to occur mainly via the kidney. Because
renal dysfunction is one of the most lethal adverse effects of
NCS in humans, it would seem prudent to reduce the kidney
accumulation of chA7Fab, conjugated to NCS.
Avidin, a 66 kDa protein found in egg whites, has a strong
avidity for biotin, a 244 Da vitamin found in low
concentrations in tissues and in blood (Mock and Dubois,
1986). The association constant of the avidin-biotin bond is
10' M-' (Green, 1963) and, as such, is 106-fold greater than
most antigen-antibody interactions. The bond formation is
completed within 15 min and, once formed, the bond is
extremely stable. The in vitro method of biotinylation of
proteins has been well described, and any type of
immunoglobulin can be biotinylated easily.
The strong affinity of the avidin-biotin system has drawn
the attention of several researchers working on background
reduction in the imaging applications of MAbs (Hnatowich et
al., 1987; Sinitsyn et al., 1989; Ogihara et al., 1994). This is
thought to be secondary to the trapping by the reticuloen-
dothelial system of avidin-biotinylated MAb aggregates
formed in the serum. These results suggested that avidin
might be useful in targeting NCS conjugated to chA7Fab
away from the kidneys. As shown in Figure 2a, a significantly
smaller amount of biotinylated chA7Fab-NCS is retained in
the blood in the groun of mice iniected with avidin comnared
with those not injected with avidin. In a previous study, '25f.
labelled chA7Fab-NCS was cleared from the blood via the
kidney and a large amount of chA7Fab-NCS accumulated
in the kidney (Otsuji et al., 1994). As shown in Figure 2h, the
kidney concentration of biotinylated chA7Fab-NCS de-
creased approximately 50% by the subsequent administra-
tion of avidin. Decreased renal dysfunction can be expected
by the administration of biotinylated chA7Fab-NCS along
with avidin. As for the tumours, the accumulation of
biotinylated chA7Fab-NCS was not affected by the
administration of avidin, while it did significantly increase
the accumulation of biotinylated chA7Fab-NCS in the
spleen and the liver. However, the splenic accumulation of
biotinylated chA7Fab conjugated to NCS is unlikely to be
toxic to patients because there have been no reports of
adverse effects of NCS on splenic function. Although a
relatively large amount of biotinylated chA7Fab-NCS also
accumulated in the liver, NCS is reported to be inactivated
rapidly in the liver (Fujita et al., 1970), which may minimise
its toxicity. In another experiment, the distribution of
biotinylated chA7Fab with a subsequent injection of avidin
was similar to that of biotinylated chA7Fab-NCS. In the
separate experiments using unbiotinylated chA7Fab with a
subsequent injection of avidin, the distribution of unbiotiny-
lated chA7Fab was identical to that without injection of
avidin (data not shown). Therefore, this high accumulation of
biotinylated chA7Fab-NCS in the spleen and the liver was
considered due to the trapping of the avidin-biotinylated
chA7Fab aggregates by the reticuloendothelial system.
Because avidin-biotinylated MAb aggregates were formed
in the serum, the immunogenity of this complex might be
enhanced. However, with the avidin doses used in this study,
we did not observe any side-effects in the animals. Other
researchers have also reported that such doses of avidin are
not toxic (Hnatowich et al., 1987; Ogihara et al., 1994;
Paganelli et al., 1990).
From these results, we conclude that the accumulation of
biotinylated chA7Fab-NCS in the blood and the kidneys
can be decreased by the subsequent administration of avidin
and this modification does not reduce tumour accumulation.
Thus, biotinylated chA7Fab may be a suitable carrier ofNCS
and result in less kidney toxicity if avidin is also
administered, preferably between 1 and 6 h after the
administration of antibody conjugate.
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